# Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)

Study · id `cardio:ct-nct02064439` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02064439](<https://clinicaltrials.gov/study/NCT02064439>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02064439

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 3365 participants.

## Technical summary

Registry record NCT02064439. Randomized; quadruple masking; primary purpose prevention. Start 2014-03-05 (actual); primary completion 2016-09-22 (actual). Results posted on 2017-12-19.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 3365 participants (enrolled count; ClinicalTrials.gov record NCT02064439, source copy `cardio:ctgov-nct02064439-2017-12-19`, retrieved 2026-10-31)
- Started: 2014-03-05 (actual) (ClinicalTrials.gov record NCT02064439, source copy `cardio:ctgov-nct02064439-2017-12-19`, retrieved 2026-10-31)
- Primary completion: 2016-09-22 (actual) (ClinicalTrials.gov record NCT02064439, source copy `cardio:ctgov-nct02064439-2017-12-19`, retrieved 2026-10-31)
- Completion: 2016-11-04 (actual) (ClinicalTrials.gov record NCT02064439, source copy `cardio:ctgov-nct02064439-2017-12-19`, retrieved 2026-10-31)
- Results first posted: 2017-12-19 (ClinicalTrials.gov record NCT02064439, source copy `cardio:ctgov-nct02064439-2017-12-19`, retrieved 2026-10-31)
- Countries: United States; Australia; Austria; Belgium; Brazil; Canada; China; Czechia; Denmark; France; Germany; Hungary; Israel; Italy; Mexico; Netherlands; New Zealand; Norway; Philippines; Poland; Russia; South Africa; South Korea; Spain; Sweden; Switzerland; Taiwan; Thailand; Türkiye; United Kingdom; Vietnam (ClinicalTrials.gov record NCT02064439, source copy `cardio:ctgov-nct02064439-2017-12-19`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02064439-2017-12-19`, retrieved 2026-10-31)

## The registry's words

- Brief title: Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
- Acronym: EinsteinChoice
- Condition: Pulmonary Embolism
- Condition: Thromboembolism
- Condition: Thrombosis
- Condition: Venous Thrombosis
- Condition: Venous Thromboembolism
- Intervention (Drug): BAY 59-7939
- Intervention (Drug): BAY 59-7939
- Intervention (Drug): ASA
- Lead sponsor: Bayer
- Lead sponsor class: INDUSTRY
- Collaborator: Janssen Scientific Affairs, LLC
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Deep vein thrombosis (`cardio:deep-vein-thrombosis`)
- Registry condition terms include this condition: Pulmonary embolism (`cardio:pulmonary-embolism`)
- Registry lists this organization as the lead sponsor: Bayer (`cardio:bayer`)
- Registry lists this organization as a collaborator: Janssen Scientific Affairs, LLC (`cardio:org-janssen-scientific-affairs-llc`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism (`cardio:pubmed-28316279`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: a86e14f27bee3ee120632b76bd72d5bdd110a9a6d7aba1d7dc534bf062875557
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
